Steven King, an advisor to iBio, has over 20 years of experience in advancing novel biologics for the treatment of cancer from discovery through late-stage clinical development including cGMP manufacturing operations to support clinical and commercial products. His experience includes over 17 years serving as president, CEO and board member of publicly traded biotechnology companies including Peregrine Pharmaceuticals, Avid Bioservices, Oncotelic and Mosaic IE. His passion is to help patients suffering from cancer and other life-threatening diseases through the development of novel production platforms and biologics that will improve and extend their quality of life.